Slides 5 Flashcards

1
Q

What is a common feature of sedative-hypnotic use ?

A

Tolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What occurs among the sedative-hypnotics and also with ethanol ?

A

Partial cross-tolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

An increase in what may contribute to tolerance with barbiturates ?

A

Drug metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

With benzodiazepines, tolerance may be due to:

A

Down regulation of brain BDZ receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Tolerance can occur with extended use of?

A

Zolpidem, but much less so with zaleplon and eszopiclone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the cause of the compulsive use of virtually all sedative-hypnotics?

A

The perceived relief of anxiety, euphoria, disinhibition, and promotion of sleep

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The consequences of abuse can be both?

A

Psychologic and physiologic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What happens when the pattern of sedative-hypnotic use becomes compulsive?

A

More serious complications develop, including tolerance and physiologic dependence.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is Physiologic dependence?

A

An altered physiologic state that requires continuous drug administration to prevent an abstinence or withdrawal syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Abstinence or withdrawal syndrome consists of?

A

1) Increased anxiety
2) Restlessness
3) Insomnia
4) CNS excitability that may progress to:
a) Convulsions
b) Weakness
c) Orthostatic hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the difference between drugs with long half-life and short half-life in terms of withdrawals?

A

Drugs with long half-life are eliminated slowly enough to accomplish gradual withdrawal with few physical symptoms.

Drugs with short half-lives may show signs of withdrawal even between doses (triazolam).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

True of False:

Withdrawal symptoms of zolpidem, zaleplon, or eszopiclone are more intense than that with BDZs

A

False; it is less intense

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

True of False:

Lethal dose range is not altered significantly by long-term use

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

True of False?

The degree of tolerance achieved is identical for all pharmacologic effects

A

False; it is not identical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What can cross-tolerance between different sedative-hypnotics, including ethanol, lead to?

A

Unsatisfactory therapeutic response when standard doses of a drug are used in a patient with a recent history of excessive use of another agent.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is Flumazenil? What type of drug is it?

A

A benzodiazepine derivative with high affinity for BDZ binding sites on GABAA receptor; Competitive antagonist.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Flumazenil blocks many of the actions of ?

A

BDZs, zolpidem, zaleplon, and eszopiclone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

True of False ?

Flumazenil does not antagonize the CNS effects of other sedative-hypnotics, ethanol, opioids or general
anesthetics.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Flumazenil is used for:

A

1) Reversing the CNS effects of BDZ overdose

2) Hastening recovery following use of BDZ in anesthesia and diagnostic procedures.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

True of False:

Antagonism of BDZ-induced respiratory depression is more predictable.

A

False; it is less predictable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is Flumazenil’s half-life?

A

It has a short half-life due to rapid hepatic clearance (0.7-1.3 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the adverse effects of Flumazenil?

A

1) Agitation, confusion, dizziness, and nausea.
2) Severe abstinence syndrome in patients with physiologic dependence
3) Seizures and cardiac arrhythmias in patients who have ingested benzodiazepines with tricyclic antidepressants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are the therapeutic effects of sedative-hypnotic drugs?

A

1) Relief of anxiety states (cause still needs to be treated)
2) Treatment of insomnia
3) Sedation and amnesia before and during medical and surgical procedures
4) Epilepsy and seizures (termination of an attack)
5) As a component of balanced anesthesia (IV)
6) For control of ethanol or other sedative-hypnotic withdrawal states
7) For muscle relaxation in specific neuromuscular disorders
8) Suppression of delirium tremens (alcohol withdrawal)
9. Drug-induced hyperexcitability states

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Which sedative-hypnotic drug is used to relieve anxiety (panic disorders and agoraphobia)?

A

Alprazolam

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Which drugs are preferred for insomnia?

A

Benzodiazepine and the newer agents over barbiturates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Which drug is used for sedation and amnesia before and during medical and surgical procedures?

A

Midazolam

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Which drug is given for suppression of delirium tremens (alcohol withdrawal)?

A

Parenteral lorazepam

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are the adverse effects of sedative-hypnotic drugs?

A

1) Relatively low doses may lead to drowsiness,
impaired judgment, and diminished motor skills
2) BDZ may cause a significant dose-related anterograde amnesia
3) Confusional states (especially in the elderly)
4) Hangover effects
5) At higher doses, may produce lethargy or a
state of exhaustion, or symptoms equivalent to
ethanol intoxication
6) Exacerbation of breathing problems in patients
with chronic pulmonary disease and those
with symptomatic sleep apnea
7) Cardiovascular collapse
8) Extensive clinical use (triazolam) has caused
behavioral disinhibition, delirium, aggression,
and violence.
9) Hypersensitivity reactions.
10) Teratogenicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What do many of the adverse effects of sedative-hypnotics result from?

A

CNS depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What causes confusional states from sedative-hypnotic drugs?

A

Overuse of sedative-hypnotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What do hangover effects include?

A

1) Drowsiness
2) Dysphoria
3) Mental or motor depression the following day

32
Q

Which drugs most commonly cause hangover effects?

A

Drugs with long half-lives

33
Q

Which patients are more sensitive to hangover effects from sedative-hypnotic drugs?

A

Elderly patients

34
Q

Barbiturates are contraindicated in patients with:

A

A history of acute intermittent porphyria

35
Q

Sedative-hypnotics have what kind of effect with CNS depressants, alcohol,
opioids, anticonvulsants, phenothiazines, antihistamines, and antidepressant drugs?

A

Additive effect

36
Q

Where can drug interactions happen including sedative-hypnotics?

A

At the level of drug metabolizing enzymes (Barbiturates induce drug metabolism)

37
Q

What is Ramelteon?

A

An agonist at melatonin receptors, MT1 and MT2, located in the suprachiasmatic nuclei of the brain.

38
Q

Melatonin receptors are thought to be involved in:

A

Maintaining the circadian rhythms underlying the sleep-wake cycle.

39
Q

Who is Ramelteon prescribed for?

A

Patients who have difficulty in falling asleep.

40
Q

What effect does Ramelteon have on GABAergic neurotransmission in the CNS?

A

NONE

41
Q

What effect does Ramelteon have on rebound insomnia or withdrawal symptoms?

A

NONE

42
Q

What is the metabolism pathway of Ramelteon?

A

Rapidly absorbed after oral administration and
undergoes extensive first-pass metabolism (CYP1A2), forming an active metabolite with a longer half-life (2-5 hours). CYP2C9 contributes.

43
Q

What induces metabolism of Ramelteon?

A

Rifampin

44
Q

Ramelteon should not be used in combination with:

A

Inhibitors of CYP1A2 (ciprofloxacin, fluvoxamine, tacrine, zileuton) or CYP2C9 (fluconazole).

45
Q

What are the adverse effects of Ramelteon?

A

1) Dizziness, somnolence, fatigue.

2) Endocrine changes (decreases testosterone levels, and increases prolactin levels)

46
Q

Ramelteon should be used with caution in patients with:

A

Liver dysfunction

47
Q

What are some Orexin receptor antagonists?

A

1) Almorexant

2) Suvorexant

48
Q

What are Orexin receptor antagonists involved in?

A

The control of wakefulness

and they are silent during sleep

49
Q

What kind of drugs are Almorexant and Suvorexant?

A

Sleep-Enabling Drugs

50
Q

What are Orexin A and B?

A

Peptides found in specific

hypothalamic neurons.

51
Q

When do Orexin levels increase and decrease?

A

Increase in the day and decrease at night.

52
Q

What is the loss of orexin neurons associated with?

A

Narcolepsy (a disorder characterized by daytime sleepiness) and Cataplexy (sudden loss of muscle tone while a person is awake).

53
Q

What is a substrate of CYP3A4?

A

Suvorexant

54
Q

How can we prolong the half-life of Suvorexant?

A

By inhibitors of the enzyme including azole antifungal drugs, clarithromycin, and verapamil.

55
Q

What kind of effect does Buspirone have?

A

A selective anxiolytic effect

56
Q

What does Buspirone do?

A

Relieves anxiety without causing marked sedation, hypnosis, or euphoria.

57
Q

What effect does Buspirone have on anticonvulsant or muscle relaxant effects?

A

NONE

58
Q

Does Buspirone interact with GABAergic systems?

A

NO

59
Q

What causes Buspirone’s anxiolytic effect?

A

Partial agonist activity at brain 5-HT1A receptors.

60
Q

What does Buspirone have affinity for?

A

Brain dopamine D2 receptors.

61
Q

What happens if you abruptly discontinue Buspirone?

A

No rebound anxiety or withdrawal signs

62
Q

Can Buspirone be used for withdrawal syndrome from

benzodiazepines or other sedative-hypnotics?

A

No, it’s not useful.

63
Q

Buspirone has __ abuse liability.

A

Minimal

64
Q

When does Buspirone’s anxiolytic effect take place?

A

3-4 weeks

65
Q

Why is Buspirone unsuitable for acute anxiety states?

A

Because its anxiolytic effect takes 3-4 weeks to be

established.

66
Q

What is Buspirone used for?

A

Generalized anxiety states but is less effective in panic disorders.

67
Q

What is the metabolism of Buspirone?

A

Rapidly absorbed orally but undergoes extensive first-pass metabolism by CYP enzymes to form several active metabolites

68
Q

One of Buspirone’s metabolites has:

A

An α2-adrenoceptor blocking action

69
Q

What is the elimination half-life of Buspirone?

A

2-4 hours

70
Q

The elimination of Buspirone is increased by __, and decreased by __.

A

Inhibitors (erythromycin,

grapefruit juice and ketoconazole) of CYP3A4; its inducers (rifampin).

71
Q

What may slow Buspirone’s clearance?

A

Liver dysfunction

72
Q

What causes less psychomotor impairment: Buspirone or BDZs?

A

Buspirone

73
Q

Does buspirone affect driving skills?

A

NO

74
Q

True or false:
Buspirone potentiates effects of conventional sedative-hypnotics, ethanol, tricyclic
antidepressants.

A

False; it does not.

75
Q

True or false:

Elderly patients are not more sensitive to Buspirone’s actions.

A

True

76
Q

What are the adverse effects of Buspirone?

A

1) Nonspecific chest pain, tachycardia, palpitations, dizziness, nervousness, headache, tinnitus
2) Gastrointestinal distress
3) Paresthesias
4) Dose-dependent pupillary constriction
5) Blood pressure may be significantly elevated in
patients receiving monoamine oxidase (MAO)
inhibitors